TXMD · TherapeuticsMD, Inc.
$2.06
-0.01 (-0.48%)
At close · Jul 28
View the 10-Q filed May 12, 2026
Going-concern doubt
— flagged May 12, 2026
Substantial doubt about the company's ability to continue as a going concern.
“The potential impact of these factors in conjunction with the uncertainty of the capital markets raises substantial doubt about our ability to continue as a going concern for the next twelve months from the issuance of these financial statements.”View the 10-Q filed May 12, 2026
Customer concentration
— top 3 customers 100% of revenue
3 customers — 100% of revenue (the three months ended March 31, 2026)
“For the three months ended March 31, 2026, 100% of license revenue related to Mayne Pharma, Theramex and Knight.”
Market Cap
$23.84M
Shares
11.57M
TherapeuticsMD, Inc. Earnings Call Transcripts
Every quarterly earnings call for TherapeuticsMD, Inc. (TXMD) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▲212.5%
$15.90M
−$49.44M
'19 Q4
20-02-20
▲210.4%
$12.25M
−$56.85M
'20 Q1
20-05-06
▲76%
$10.70M
−$51.98M
'20 Q2
20-08-06
▼18.5%
$19.34M
−$32.61M
'20 Q3
20-11-09
▲42%
$22.58M
−$42.09M
'20 Q4
21-03-02
▲62.2%
$19.87M
−$39.38M
'21 Q1
21-05-06
▲114.9%
$23.00M
−$42.65M
'21 Q2
21-08-04
▲31.4%
$25.41M
−$47.42M
'21 Q3
21-11-12
▼17.3%
$18.68M
−$42.96M
'21 Q4
22-03-10
▼96.5%
$695,000
−$49.02M
'22 Q1
22-05-16
▼98.5%
$348,000
$112.28M
'22 Q2
22-08-15
LATEST
▼98.6%
$354,000
−$28.96M
'22 Q3
22-11-14
Earnings call
FY22 · Q3
2022-11-14
TherapeuticsMD, Inc. Q3 FY2022 Earnings Call
Revenue
$354,000
▼ 98.6% YoY Diluted EPS
$-3.13
Gross margin
0.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-15
TherapeuticsMD, Inc. Q2 FY2022 Earnings Call
Revenue
$348,000
▼ 98.5% YoY Diluted EPS
$12.83
Gross margin
0.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-16
TherapeuticsMD, Inc. Q1 FY2022 Earnings Call
Revenue
$695,000
▼ 96.5% YoY Diluted EPS
$-5.70
Gross margin
2082.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-03-10
TherapeuticsMD, Inc. Q4 FY2021 Earnings Call
Revenue
$18.68M
▼ 17.3% YoY Gross margin
74.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-12
TherapeuticsMD, Inc. Q3 FY2021 Earnings Call
Revenue
$25.41M
▲ 31.4% YoY Diluted EPS
$-5.62
Gross margin
79.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-04
TherapeuticsMD, Inc. Q2 FY2021 Earnings Call
Revenue
$23.00M
▲ 114.9% YoY Diluted EPS
$-5.41
Gross margin
82.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-06
TherapeuticsMD, Inc. Q1 FY2021 Earnings Call
Revenue
$19.87M
▲ 62.2% YoY Gross margin
76.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-03-02
TherapeuticsMD, Inc. Q4 FY2020 Earnings Call
Revenue
$22.58M
▲ 42% YoY Gross margin
75.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-11-09
TherapeuticsMD, Inc. Q3 FY2020 Earnings Call
Revenue
$19.34M
▼ 18.5% YoY Gross margin
83.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-08-06
TherapeuticsMD, Inc. Q2 FY2020 Earnings Call
Revenue
$10.70M
▲ 76% YoY Gross margin
58.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-05-06
TherapeuticsMD, Inc. Q1 FY2020 Earnings Call
Revenue
$12.25M
▲ 210.4% YoY Gross margin
77.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-02-20
TherapeuticsMD, Inc. Q4 FY2019 Earnings Call
Revenue
$15.90M
▲ 212.5% YoY Gross margin
81.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Showing 1–12 of 12 earnings calls